Fortunately, after more decade of research, a drug Herceptin (generic name trastuzmab) was discovered and approved for use by the U.S. Food and Drug Administration (FDA) in September 1998, which can be very successful in treatment of advanced breast cancer just for women whose breast cancer cells carry extra copies of a HER2. This evidence concerns the gene ERBB2 and breast carcinoma.